Bronchial Challenge Test of Magnesium-treated Asthmatics
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01118923|
Recruitment Status : Completed
First Posted : May 7, 2010
Last Update Posted : September 4, 2013
The present study is part of a project titled 'Magnesium in asthma and chronic obstructive pulmonary disease'. The hypothesis of the main project is that a daily magnesium supplement will benefit patients with asthma and chronic obstructive pulmonary disease.
The aim of this part of the project is to study the effect of a daily magnesium supplement on the grade of bronchial hyperreactivity in asthmatics.
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Dietary Supplement: Magnesium supplement (magnesium hydroxide/ -oxide) Dietary Supplement: Placebo||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Metacholine-provocation of Mablet-treated Asthmatics|
|Study Start Date :||October 2010|
|Actual Primary Completion Date :||March 2013|
|Actual Study Completion Date :||March 2013|
|No Intervention: Washout|
|Active Comparator: Mablet||
Dietary Supplement: Magnesium supplement (magnesium hydroxide/ -oxide)
3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
Other Name: Mablet
|Placebo Comparator: Placebo||
Dietary Supplement: Placebo
3 placebo-tablets daily for 12 weeks
- PD20 for metacholine [ Time Frame: Two years ]Bronchial hyperreactivity is expressed by the dose of inhaled metacholine necessary to achieve a decline of 20 % in FEV1 (Bronchial challenge test).
- Impulse Oscillometry for measurement of pulmonary impedance [ Time Frame: Two years ]A characteristic feature of Impulse Oscillometry is that pulmonary impedance is not derived from the respiratory signals but from the pressure-flow relationship of artificial impulse-shaped test signals which are produced by an external generator. The advantage of artificial test signals is the incomparably higher frequency contents with a relatively high consistency as far as frequency range and amplitude are concerned, so that a thorough differentiation of pulmonary function is possible.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01118923
|Research Dept. of Respiratory Medicine, Aarhus University Hospital|
|Aarhus C, Denmark, 8000|
|Principal Investigator:||Ronald Dahl, Professor||Dept. of Respiratory Medicine, Aarhus University Hospital, Aarhus, Denmark|